Drugs interactions for Jardiance®
- 0 Major drug interactions
- 267 Moderate drug interactions (including ingredients like Acarbose, Acebutolol, Acetylsalicylic acid)
- 145 Minor drug interactions (including ingredients like Abaloparatide, Acetazolamide, Acetyl sulfisoxazole)
412 interactions for Jardiance®Empagliflozin may increase the hypoglycemic activities of Acarbose.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Acebutolol.The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Empagliflozin.Empagliflozin may increase the hypoglycemic activities of Alogliptin.The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Empagliflozin.Aminosalicylic acid may increase the hypoglycemic activities of Empagliflozin.The risk or severity of hypoglycemia can be increased when Amiodarone is combined with Empagliflozin.Amitriptyline may decrease the hypoglycemic activities of Empagliflozin.The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Empagliflozin.Amobarbital may increase the hypotensive activities of Empagliflozin.Amoxapine may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Aripiprazole.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Arsenic trioxide.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Articaine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Asenapine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Atazanavir.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Atenolol.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Baclofen.Balsalazide may increase the hypoglycemic activities of Empagliflozin.The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Benazepril is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Betaxolol.Empagliflozin may increase the hypoglycemic activities of Bexagliflozin.Bismuth subsalicylate may increase the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Bisoprolol.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Brexpiprazole.Empagliflozin may increase the hypoglycemic activities of Bromocriptine.The risk or severity of hyperglycemia can be increased when Budesonide is combined with Empagliflozin.Butalbital may increase the hypotensive activities of Empagliflozin.Canagliflozin may increase the hypoglycemic activities of Empagliflozin.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Captopril.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Carvedilol.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ceritinib.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Chlorpromazine.Choline salicylate may increase the hypoglycemic activities of Empagliflozin.The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Ciprofloxacin.The risk or severity of hypoglycemia can be increased when Citalopram is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Empagliflozin.Clomipramine may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Clozapine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Conjugated estrogens.The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dabrafenib.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Danazol.Dapagliflozin may increase the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Darunavir.The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Delafloxacin.Desipramine may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Desogestrel.The risk or severity of hyperglycemia can be increased when Desonide is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Dexamethasone acetate is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Diazoxide.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dienogest.The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Empagliflozin.Diflunisal may increase the hypoglycemic activities of Empagliflozin.The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Empagliflozin.Empagliflozin may increase the hypoglycemic activities of Disopyramide.Doxepin may decrease the hypoglycemic activities of Empagliflozin.Empagliflozin may increase the hypoglycemic activities of Dulaglutide.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Enalapril.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Enalaprilat.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Epinephrine.Empagliflozin may increase the hypoglycemic activities of Ertugliflozin.The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estetrol.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estradiol.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estrone sulfate.Ethanol may increase the hypotensive activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethinylestradiol.The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethynodiol diacetate.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Etonogestrel.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Everolimus.Empagliflozin may increase the hypoglycemic activities of Exenatide.The risk or severity of hypoglycemia can be increased when Felodipine is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Fluconazole.The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Fosamprenavir.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Fosinopril.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Gatifloxacin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Gemifloxacin.Empagliflozin may increase the hypoglycemic activities of Glimepiride.Empagliflozin may increase the hypoglycemic activities of Glipizide.Empagliflozin may increase the hypoglycemic activities of Glyburide.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Goserelin.The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Haloperidol.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Histrelin.The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Hydroxychloroquine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydroxyprogesterone caproate.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Iloperidone.Imipramine may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Indinavir.The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin aspart.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin degludec.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin detemir.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin glargine.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin glulisine.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin human.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin lispro.Isocarboxazid may increase the orthostatic hypotensive activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Isoniazid.The risk or severity of hypoglycemia can be increased when Isradipine is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Labetalol.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lanreotide.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Leuprolide.The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Levofloxacin.The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Levonorgestrel.Linezolid may increase the orthostatic hypotensive activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Liothyronine.The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Empagliflozin.Empagliflozin may increase the hypoglycemic activities of Liraglutide.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Lisinopril.Empagliflozin may increase the hypoglycemic activities of Lixisenatide.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Lomefloxacin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lonapegsomatropin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lopinavir.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lurasidone.The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Empagliflozin.Empagliflozin may increase the hypoglycemic activities of Mecasermin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.The risk or severity of hyperglycemia can be increased when Medrysone is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Megestrol acetate.Mesalazine may increase the hypoglycemic activities of Empagliflozin.Methohexital may increase the hypotensive activities of Empagliflozin.The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Empagliflozin.Methyl salicylate may increase the hypoglycemic activities of Empagliflozin.Methylene blue may increase the orthostatic hypotensive activities of Empagliflozin.The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Metoprolol.Empagliflozin may increase the hypoglycemic activities of Mifepristone.Empagliflozin may increase the hypoglycemic activities of Miglitol.The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Empagliflozin.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Moexipril.The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Moxifloxacin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Nadolol.Empagliflozin may increase the hypoglycemic activities of Nateglinide.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Nebivolol.The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nelfinavir.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Niacin.The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Nifedipine is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nilotinib.The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Norethisterone.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Norgestimate.Nortriptyline may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Octreotide.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Ofloxacin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Olanzapine.Olsalazine may increase the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Paliperidone.The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pasireotide.The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Empagliflozin.Empagliflozin may increase the hypoglycemic activities of Pentamidine.Pentobarbital may increase the hypotensive activities of Empagliflozin.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Perindopril.Phenelzine may increase the orthostatic hypotensive activities of Empagliflozin.Phenobarbital may increase the hypotensive activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Phentermine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Phenytoin.The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Pindolol.Empagliflozin may increase the hypoglycemic activities of Pioglitazone.Empagliflozin may increase the hypoglycemic activities of Pramlintide.The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Prednisone is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Empagliflozin.Primidone may increase the hypotensive activities of Empagliflozin.Procaine may increase the orthostatic hypotensive activities of Empagliflozin.Procarbazine may increase the orthostatic hypotensive activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Progesterone.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Propafenone.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Propranolol.Protriptyline may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pseudoephedrine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Quetiapine.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Quinapril.Empagliflozin may increase the hypoglycemic activities of Quinine.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Ramipril.Rasagiline may increase the orthostatic hypotensive activities of Empagliflozin.Empagliflozin may increase the hypoglycemic activities of Repaglinide.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ritonavir.Empagliflozin may increase the hypoglycemic activities of Rosiglitazone.Safinamide may increase the orthostatic hypotensive activities of Empagliflozin.Salicylic acid may increase the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Saquinavir.Empagliflozin may increase the hypoglycemic activities of Saxagliptin.Secobarbital may increase the hypotensive activities of Empagliflozin.Selegiline may increase the orthostatic hypotensive activities of Empagliflozin.Empagliflozin may increase the hypoglycemic activities of Semaglutide.The risk or severity of hypoglycemia can be increased when Sertraline is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Sirolimus.Empagliflozin may increase the hypoglycemic activities of Sitagliptin.The risk or severity of hypotension can be increased when Sodium ferric gluconate complex is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Somapacitan.Somatotropin may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Somatrogon.Empagliflozin may increase the hypoglycemic activities of Sotagliflozin.The risk or severity of hypoglycemia can be increased when Sotalol is combined with Empagliflozin.Empagliflozin may increase the hypoglycemic activities of Sulfadiazine.Empagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.Sulfasalazine may increase the hypoglycemic activities of Empagliflozin.Empagliflozin may increase the hypoglycemic activities of Sunitinib.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tacrolimus.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Temsirolimus.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Teprotumumab.Thyroid, porcine may decrease the hypoglycemic activities of Empagliflozin.Thyrotropin alfa may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Timolol.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tipranavir.Empagliflozin may increase the hypoglycemic activities of Tirzepatide.The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Empagliflozin.Empagliflozin may increase the hypoglycemic activities of Tolazamide.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Trandolapril.Tranylcypromine may increase the orthostatic hypotensive activities of Empagliflozin.The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Empagliflozin.Trimipramine may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Triptorelin.Trolamine salicylate may increase the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Trovafloxacin.The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Vamorolone is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Verapamil is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Vorinostat.The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ziprasidone.The risk or severity of adverse effects can be increased when Abaloparatide is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Acetazolamide.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Acetyl sulfisoxazole.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Albuterol.The risk or severity of adverse effects can be increased when Aldesleukin is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Aliskiren is combined with Empagliflozin.Empagliflozin may increase the hypotensive activities of Ambrisentan.The risk or severity of adverse effects can be increased when Amifostine is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Amiloride.The risk or severity of adverse effects can be increased when Amphotericin B is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Apomorphine is combined with Empagliflozin.Empagliflozin may increase the hypotensive activities of Aprocitentan.Aripiprazole lauroxil may increase the hypotensive activities of Empagliflozin.The risk or severity of hypotension can be increased when Avanafil is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Bendroflumethiazide.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Bosentan.The risk or severity of adverse effects can be increased when Bretylium is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Brinzolamide.Empagliflozin may increase the diuretic activities of Bromotheophylline.Empagliflozin may increase the diuretic activities of Bumetanide.The risk or severity of adverse effects can be increased when Bupivacaine is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Celecoxib.Empagliflozin may increase the diuretic activities of Chlorothiazide.Empagliflozin may increase the diuretic activities of Chlorthalidone.The risk or severity of adverse effects can be increased when Clofarabine is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Clonidine is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Conivaptan.Empagliflozin may increase the hypotensive activities of Dasiglucagon.The risk or severity of adverse effects can be increased when Desflurane is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Diclofenamide.The risk or severity of adverse effects can be increased when Empagliflozin is combined with Dinutuximab.The risk or severity of adverse effects can be increased when Dipyridamole is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Dorzolamide.The risk or severity of adverse effects can be increased when Doxazosin is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Drospirenone.The risk or severity of orthostatic hypotension and syncope can be increased when Empagliflozin is combined with Duloxetine.Empagliflozin may increase the diuretic activities of Eplerenone.The risk or severity of adverse effects can be increased when Epoprostenol is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Eprosartan is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Esmolol is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Etacrynic acid.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Fedratinib.The risk or severity of adverse effects can be increased when Fenoldopam is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Finerenone.Fluoxymesterone may increase the hypoglycemic activities of Empagliflozin.The risk or severity of hypotension can be increased when Fostamatinib is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Furosemide.The risk or severity of adverse effects can be increased when Guanfacine is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Hydralazine is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Hydrochlorothiazide.Empagliflozin may increase the diuretic activities of Hydroflumethiazide.The risk or severity of adverse effects can be increased when Iloprost is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Indapamide.The risk or severity of adverse effects can be increased when Irbesartan is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Isoflurane is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Isosorbide.The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Empagliflozin.The risk or severity of thrombocytopenia can be increased when Empagliflozin is combined with Ketotifen.Empagliflozin may increase the hypotensive activities of Landiolol.The risk or severity of hypotension and orthostatic hypotension can be increased when Empagliflozin is combined with Levodopa.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Levothyroxine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lithium carbonate.The risk or severity of adverse effects can be increased when Lofexidine is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Losartan is combined with Empagliflozin.Empagliflozin may increase the hypotensive activities of Macitentan.Empagliflozin may increase the diuretic activities of Mannitol.The risk or severity of adverse effects can be increased when Mecamylamine is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Methazolamide.The risk or severity of adverse effects can be increased when Methyldopa is combined with Empagliflozin.Methyltestosterone may increase the hypoglycemic activities of Empagliflozin.Empagliflozin may increase the diuretic activities of Metolazone.Empagliflozin may increase the hypotensive activities of Metyrosine.The risk or severity of adverse effects can be increased when Minoxidil is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Mitapivat.The risk or severity of adverse effects can be increased when Morphine is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Nabilone is combined with Empagliflozin.Nandrolone decanoate may increase the hypoglycemic activities of Empagliflozin.The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Nitroprusside is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Empagliflozin is combined with Nitrous acid.The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Olmesartan is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Empagliflozin is combined with Opicapone.Oxandrolone may increase the hypoglycemic activities of Empagliflozin.Oxymetholone may increase the hypoglycemic activities of Empagliflozin.The risk or severity of adverse effects can be increased when Paclitaxel is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Papaverine is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Phentolamine is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Polythiazide.Empagliflozin may increase the diuretic activities of Potassium.Empagliflozin may increase the diuretic activities of Potassium cation.Empagliflozin may increase the diuretic activities of Potassium citrate.The risk or severity of adverse effects can be increased when Pramipexole is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Prazosin is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Probenecid.The risk or severity of adverse effects can be increased when Propofol is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Remifentanil is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Reserpine is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Riociguat is combined with Empagliflozin.Empagliflozin may increase the hypotensive activities of Risperidone.The risk or severity of adverse effects can be increased when Ropinirole is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Ropivacaine is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Rosuvastatin.The risk or severity of adverse effects can be increased when Rotigotine is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Empagliflozin is combined with Sacubitril.Empagliflozin may increase the hypotensive activities of Selexipag.The risk or severity of adverse effects can be increased when Sevoflurane is combined with Empagliflozin.The risk or severity of hypotension can be increased when Sildenafil is combined with Empagliflozin.Empagliflozin may increase the hypotensive activities of Sotatercept.Empagliflozin may increase the diuretic activities of Spironolactone.The risk or severity of adverse effects can be increased when Sufentanil is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sulfamethizole.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sumatriptan.Empagliflozin may increase the hypotensive activities of Tadalafil.The risk or severity of adverse effects can be increased when Tamsulosin is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Telmisartan is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Terazosin is combined with Empagliflozin.Testosterone may increase the hypoglycemic activities of Empagliflozin.Testosterone cypionate may increase the hypoglycemic activities of Empagliflozin.Testosterone enanthate may increase the hypoglycemic activities of Empagliflozin.Testosterone propionate may increase the hypoglycemic activities of Empagliflozin.Testosterone undecanoate may increase the hypoglycemic activities of Empagliflozin.The risk or severity of adverse effects can be increased when Thalidomide is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Thioridazine is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Tizanidine is combined with Empagliflozin.Empagliflozin may increase the hypotensive activities of Tocopherylquinone.The risk or severity of adverse effects can be increased when Tolcapone is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Tolvaptan.Empagliflozin may increase the diuretic activities of Torasemide.Empagliflozin may increase the hypotensive activities of Treprostinil.Empagliflozin may increase the diuretic activities of Triamterene.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Valdecoxib.The risk or severity of adverse effects can be increased when Valsartan is combined with Empagliflozin.The risk or severity of hypotension can be increased when Vardenafil is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Vemurafenib.The risk or severity of adverse effects can be increased when Empagliflozin is combined with Vericiguat.Empagliflozin may increase the diuretic activities of Zonisamide.
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and Jardiance®.
Acarbose
Acebutolol
Acetylsalicylic acid
Alclometasone
Alogliptin
Amcinonide
Aminosalicylic acid
Amiodarone
Amitriptyline
Amlodipine
Amobarbital
Amoxapine
Aripiprazole
Arsenic trioxide
Articaine
Asenapine
Atazanavir
Atenolol
Baclofen
Balsalazide
Beclomethasone dipropionate
Benazepril
Betamethasone
Betaxolol
Bexagliflozin
Bismuth subsalicylate
Bisoprolol
Brexpiprazole
Bromocriptine
Budesonide
Butalbital
Canagliflozin
Captopril
Carvedilol
Ceritinib
Chlorpromazine
Choline salicylate
Ciclesonide
Ciprofloxacin
Citalopram
Clevidipine
Clobetasol propionate
Clocortolone
Clomipramine
Clozapine
Conjugated estrogens
Corticotropin
Cortisone acetate
Dabrafenib
Danazol
Dapagliflozin
Darunavir
Deflazacort
Delafloxacin
Desipramine
Desogestrel
Desonide
Desoximetasone
Desvenlafaxine
Dexamethasone
Dexamethasone acetate
Diazoxide
Dienogest
Diflorasone
Diflunisal
Difluprednate
Diltiazem
Disopyramide
Doxepin
Dulaglutide
Enalapril
Enalaprilat
Epinephrine
Ertugliflozin
Escitalopram
Estetrol
Estradiol
Estrone sulfate
Ethanol
Ethinylestradiol
Ethosuximide
Ethynodiol diacetate
Etonogestrel
Everolimus
Exenatide
Felodipine
Fluconazole
Fludrocortisone
Flunisolide
Fluocinolone acetonide
Fluocinonide
Fluorometholone
Fluoxetine
Flurandrenolide
Fluticasone furoate
Fluticasone propionate
Fluvoxamine
Fosamprenavir
Fosinopril
Gatifloxacin
Gemifloxacin
Glimepiride
Glipizide
Glyburide
Goserelin
Halcinonide
Haloperidol
Histrelin
Hydrocortisone
Hydrocortisone acetate
Hydrocortisone butyrate
Hydrocortisone probutate
Hydrocortisone succinate
Hydrocortisone valerate
Hydroxychloroquine
Hydroxyprogesterone caproate
Iloperidone
Imipramine
Indinavir
Indomethacin
Insulin aspart
Insulin degludec
Insulin detemir
Insulin glargine
Insulin glulisine
Insulin human
Insulin lispro
Isocarboxazid
Isoniazid
Isradipine
Labetalol
Lanreotide
Leuprolide
Levamlodipine
Levofloxacin
Levomilnacipran
Levonorgestrel
Linezolid
Liothyronine
Lipoic acid
Liraglutide
Lisinopril
Lixisenatide
Lomefloxacin
Lonapegsomatropin
Lopinavir
Lurasidone
Magnesium sulfate
Mecasermin
Medroxyprogesterone acetate
Medrysone
Megestrol acetate
Mesalazine
Methohexital
Methsuximide
Methyl salicylate
Methylene blue
Methylprednisolone
Methylprednisolone hemisuccinate
Metoprolol
Mifepristone
Miglitol
Milnacipran
Moexipril
Mometasone furoate
Moxifloxacin
Nadolol
Nateglinide
Nebivolol
Nefazodone
Nelfinavir
Niacin
Nicardipine
Nifedipine
Nilotinib
Nimodipine
Nisoldipine
Norethisterone
Norgestimate
Nortriptyline
Octreotide
Ofloxacin
Olanzapine
Olsalazine
Paliperidone
Paroxetine
Pasireotide
Pegvisomant
Pentamidine
Pentobarbital
Perindopril
Phenelzine
Phenobarbital
Phentermine
Phenytoin
Pinaverium
Pindolol
Pioglitazone
Pramlintide
Prednicarbate
Prednisolone
Prednisolone acetate
Prednisolone phosphate
Prednisone
Pregabalin
Primidone
Procaine
Procarbazine
Progesterone
Propafenone
Propranolol
Protriptyline
Pseudoephedrine
Quetiapine
Quinapril
Quinine
Ramipril
Rasagiline
Repaglinide
Ritonavir
Rosiglitazone
Safinamide
Salicylic acid
Saquinavir
Saxagliptin
Secobarbital
Selegiline
Semaglutide
Sertraline
Sirolimus
Sitagliptin
Sodium ferric gluconate complex
Somapacitan
Somatotropin
Somatrogon
Sotagliflozin
Sotalol
Sulfadiazine
Sulfamethoxazole
Sulfasalazine
Sunitinib
Tacrolimus
Temsirolimus
Teprotumumab
Thyroid, porcine
Thyrotropin alfa
Timolol
Tipranavir
Tirzepatide
Tixocortol
Tolazamide
Trandolapril
Tranylcypromine
Triamcinolone
Trimipramine
Triptorelin
Trolamine salicylate
Trovafloxacin
Ubidecarenone
Ulobetasol
Vamorolone
Venlafaxine
Verapamil
Vorinostat
Xylometazoline
Ziconotide
Ziprasidone
Abaloparatide
Acetazolamide
Acetyl sulfisoxazole
Albuterol
Aldesleukin
Aliskiren
Ambrisentan
Amifostine
Amiloride
Amphotericin B
Amyl Nitrite
Apomorphine
Aprocitentan
Aripiprazole lauroxil
Avanafil
Azilsartan medoxomil
Bendroflumethiazide
Bosentan
Bretylium
Brinzolamide
Bromotheophylline
Bumetanide
Bupivacaine
Candesartan cilexetil
Celecoxib
Chlorothiazide
Chlorthalidone
Clofarabine
Clonidine
Conivaptan
Dasiglucagon
Desflurane
Dexmedetomidine
Diclofenamide
Dinutuximab
Dipyridamole
Dorzolamide
Doxazosin
Drospirenone
Duloxetine
Eplerenone
Epoprostenol
Eprosartan
Esmolol
Etacrynic acid
Fedratinib
Fenoldopam
Finerenone
Fluoxymesterone
Fostamatinib
Furosemide
Guanfacine
Hydralazine
Hydrochlorothiazide
Hydroflumethiazide
Iloprost
Indapamide
Irbesartan
Isoflurane
Isosorbide
Isosorbide dinitrate
Isosorbide mononitrate
Isoxsuprine
Ketotifen
Landiolol
Levodopa
Levothyroxine
Lithium carbonate
Lofexidine
Losartan
Macitentan
Mannitol
Mecamylamine
Methazolamide
Methyldopa
Methyltestosterone
Metolazone
Metyrosine
Minoxidil
Mitapivat
Morphine
Nabilone
Nandrolone decanoate
Nitric Oxide
Nitroglycerin
Nitroprusside
Nitrous acid
Obinutuzumab
Olmesartan
Opicapone
Oxandrolone
Oxymetholone
Paclitaxel
Papaverine
Phenoxybenzamine
Phentolamine
Polythiazide
Potassium
Potassium cation
Potassium citrate
Pramipexole
Prazosin
Probenecid
Propofol
Remifentanil
Reserpine
Riociguat
Risperidone
Ropinirole
Ropivacaine
Rosuvastatin
Rotigotine
Sacubitril
Selexipag
Sevoflurane
Sildenafil
Sotatercept
Spironolactone
Sufentanil
Sulfamethizole
Sumatriptan
Tadalafil
Tamsulosin
Telmisartan
Terazosin
Testosterone
Testosterone cypionate
Testosterone enanthate
Testosterone propionate
Testosterone undecanoate
Thalidomide
Thioridazine
Tizanidine
Tocopherylquinone
Tolcapone
Tolvaptan
Torasemide
Treprostinil
Triamterene
Valdecoxib
Valsartan
Vardenafil
Vemurafenib
Vericiguat
Zonisamide